This recombinant monoclonal antibody is developed as a research-grade biosimilar to LM-168, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. This interaction delivers inhibitory signals that dampen immune responses and maintain peripheral tolerance. Dysregulation of CTLA4 signaling is implicated in various autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease, while its expression on regulatory T cells contributes to tumor immune evasion in multiple cancers.
LM-168 serves as a reference antibody for investigating CTLA4-mediated immune regulation and checkpoint blockade mechanisms. This biosimilar provides researchers with a reliable tool for studying T-cell activation dynamics, immune tolerance pathways, and therapeutic strategies targeting immune checkpoints. It supports investigations in immunology, oncology, and autoimmune disease research, facilitating the development of novel immunotherapeutic approaches.
Email: support@cusabio.com
Distributors Worldwide